OPKO Health (NASDAQ:OPK) Upgraded at StockNews.com

StockNews.com upgraded shares of OPKO Health (NASDAQ:OPK) from a sell rating to a hold rating in a report published on Wednesday morning.

Other analysts have also issued reports about the company. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th. Finally, Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th.

OPKO Health Price Performance

Shares of NASDAQ:OPK opened at $1.54 on Wednesday. OPKO Health has a twelve month low of $0.85 and a twelve month high of $1.76. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.05 billion, a PE ratio of -8.11 and a beta of 1.62. The company’s 50 day moving average is $1.54 and its 200 day moving average is $1.48.

Insider Activity

In related news, CEO Phillip Md Et Al Frost bought 500,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were acquired at an average price of $1.56 per share, for a total transaction of $780,000.00. Following the completion of the transaction, the chief executive officer now directly owns 212,411,477 shares in the company, valued at $331,361,904.12. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders acquired 1,304,255 shares of company stock worth $2,024,605 over the last three months. 47.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Asset Management Inc raised its stake in OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 8,978 shares during the last quarter. PFG Investments LLC raised its position in shares of OPKO Health by 2.5% in the second quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock valued at $1,201,000 after buying an additional 23,700 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of OPKO Health in the second quarter valued at about $112,000. Y.D. More Investments Ltd purchased a new position in shares of OPKO Health in the second quarter worth about $1,840,000. Finally, Hollencrest Capital Management boosted its position in OPKO Health by 14.0% during the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 11,020 shares during the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.